logo
#

Latest news with #RobertFord

Abbott Laboratories (ABT): I Am Very Upset With Abbott,' Says Jim Cramer
Abbott Laboratories (ABT): I Am Very Upset With Abbott,' Says Jim Cramer

Yahoo

time21-07-2025

  • Business
  • Yahoo

Abbott Laboratories (ABT): I Am Very Upset With Abbott,' Says Jim Cramer

We recently published . Abbott Laboratories (NYSE:ABT) is one of the stocks Jim Cramer recently discussed. Abbott Laboratories (NYSE:ABT) is a healthcare company. While it was one of Cramer's top stocks for most of this year, this show saw the CNBC TV host take a different tone. Abbott Laboratories (NYSE:ABT)'s shares fell by 8.5% in July after the firm's latest earnings results saw it warn about a massive $1 billion hit in 2025 from tariffs. Here's what Cramer said about the firm: 'I am very upset with Abbott. They're on tonight. I have supported the company for years and years. It's the diagnostic business. We'll have Robert Ford on tonight, it's not catastrophic because I like the company, long term. But, this is not, this was another thing that happened this morning that I found quite disturbing. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Previously, Cramer discussed Abbott Laboratories (NYSE:ABT)'s earnings before the release: 'Then one of my absolute favorite companies, medical device maker, Abbott Labs reports. And you know, I always like to tell you which companies tend to be misinterpreted in a negative way during the earnings season. Abbott's a textbook example. It bothers me, but there are always sellers who claim to be disappointed. So, if you don't own any Abbott, may I suggest that you wait to see the numbers, wait for the stock's opening, wait for the sellers to appear. Patience is a virtue with ABT.' While we acknowledge the potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Abbott Laboratories (ABT) Drops on Lower Full-Year Guidance
Abbott Laboratories (ABT) Drops on Lower Full-Year Guidance

Yahoo

time18-07-2025

  • Business
  • Yahoo

Abbott Laboratories (ABT) Drops on Lower Full-Year Guidance

We recently published . Abbott Laboratories (NYSE:ABT) is one of the worst-performing companies on Thursday. Abbott Laboratories declined by 8.52 percent on Thursday to end at $120.51 apiece as investors were disheartened by the lowering of its full-year guidance. For the full year, Abbott Laboratories (NYSE:ABT) now projects organic sales growth, excluding COVID-19 testing-related sales, to grow between 7.5 to 8 percent, or 6 to 7 percent when including COVID-19 testing-related sales. Adjusted diluted earnings per share were pegged at $5.1 to $5.2 for the full year, while adjusted diluted EPS were expected to settle at $1.28 to $1.32 for the third quarter of the year. In an interview on CNBC, Abbott Laboratories (NYSE:ABT) CEO Robert Ford deemed the drop an 'overreaction.' 'I think this is a little bit of an overreaction. Of course, we are all over this,' Ford said. 'We're focused on this, but the fundamentals of the entire rest of the company are pretty much intact, and this is just really a point in time that we have to get through.' An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. In the second quarter of the year, Abbott Laboratories (NYSE:ABT) grew its net income by 36.7 percent to $1.779 billion from $1.3 billion in the same period last year. Net sales increased by 7.4 percent to $11.142 billion from $10.377 billion year-on-year. While we acknowledge the potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

10 things to watch in the stock market Friday, including earnings and merger talks
10 things to watch in the stock market Friday, including earnings and merger talks

CNBC

time18-07-2025

  • Business
  • CNBC

10 things to watch in the stock market Friday, including earnings and merger talks

The Club's 10 things to watch Friday, July 18 — Today's newsletter was written by Jeff Marks, the Club's director of portfolio analysis. 1. Stock futures are muted to close out the week this morning. The S & P 500 closed at a new all-time high yesterday, and all three major averages are on pace for winning weeks amid a string of strong earnings reports. 2. Netflix reported a small second-quarter revenue and earnings per share beat last night. Its 16% year-over-year revenue growth was driven by an increase in subscriptions, higher pricing and increased ad revenue. While shares dropped more than 2% this morning, several analysts raise their price targets north of $1,500. 3. 3M beat on revenues and adjusted EPS of $2.16 exceeded the consensus of $2.10. Organic sales growth was up 1.5%. The industrial conglomerate now sees a smaller full-year tariff impact than previously expected. It raised its full-year earnings per share outlook, including tariff impact. Its previous guidance did not include the impact of tariffs. 4. American Express reported a solid revenue and adjusted earnings per share beat this morning. It also reaffirmed its full-year guidance. Total travel-and-entertainment business increased 5%, driven by 8% growth in restaurants. Shares rose about 1%. 5. Club name Abbott Laboratories was upgraded to buy at Jefferies following Thursday's ugly sell-off in reaction to the company's slight cut to its growth outlook. Many others came to the stock's defense, and CEO Robert Ford told Jim Cramer last night he thought the stock pullback was "a little bit of an overreaction." 6. Dupont named a catalyst call buy idea at Deutsche Bank into second-quarter earnings. It's the last report before its electronics business is spun off on Nov. 1, and Deutsche Bank argued the Club stock trades at too steep of a discount to its estimated sum-of-the-parts value. 7. Oilfield services provider SLB reported better-than-expected second-quarter revenue while adjusted earnings per share beat by a penny. The company said "customers have selectively adjusted activity, prioritizing key projects and planning cautiously, particularly in offshore deepwater markets." 8. Chevron's $53 billion acquisition of Hess Corporation is set to close after winning an international court case against rival Exxon Mobil in a battle over Hess's offshore oil assets in Guyana. The legal fight had delayed the deal's closing. 9. Shares of Talen Energy are up more than 10% after the company says its buying gas fired power plants in Pennsylvania and Ohio for $3.5 billion after estimated tax benefits. It's all part of the growing power needs of the AI race. 10. Union Pacific is exploring an acquisition of railroad peer Norfolk Southern , The Wall Street Journal reported yesterday evening. The deal would be a big one, with Norfolk Southern's market cap being roughly $60 billion, and turn Union Pacific into a coast-to-coast operator. Sign up for my Top 10 Morning Thoughts on the Market email newsletter for free (See here for a full list of the stocks at Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.

Abbott lowers sales forecast on diagnostics decline, US funding cuts
Abbott lowers sales forecast on diagnostics decline, US funding cuts

Yahoo

time18-07-2025

  • Business
  • Yahoo

Abbott lowers sales forecast on diagnostics decline, US funding cuts

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers Q2 revenue: $11.14 billion 7.4% increase year over year Medical device sales: $5.37 billion 13.4% increase year over year Diagnostics sales: $2.17 billion 1% decrease year over year Abbott lowered its sales forecast for the year, citing a drop in diagnostic testing. CEO Robert Ford told investors on Thursday that the company is seeing a drop-off in COVID-19 testing sales, challenges in China's core laboratory market and a reduction in U.S. foreign aid funding for HIV testing, with a combined impact of more than $1 billion. The company reduced its 2025 organic sales growth forecast to a range of 6% to 7%, from the previous forecast of 7.5% to 8.5% shared in the first quarter. 'Even with that billion dollars, we're still forecasting high single-digit growth and absorbing the impact of tariffs,' Ford said. The company now expects 'just under $200 million' of impact from tariffs. CFO Phil Boudreau said the amount was down from previous estimates, when the company had outlined 'a few hundred million' in tariff costs. Discussing how the company plans to mitigate tariffs, Ford said that Abbott plans to open a new cardiovascular manufacturing facility in Georgia in 2028. 'Once tariffs get set in place, they're very difficult to walk away from,' the CEO said, 'so we have to think medium term, but also long term.' Growth in medical devices, diabetes A bright spot for Abbott was its medical device segment, which grew by more than 13% to $5.37 billion in sales. The company's diabetes segment grew by more than 20% to $1.98 billion. Analysts asked about Abbott's plans for a dual analyte sensor that would provide glucose and ketone readings. The company recently showcased the device during the American Diabetes Association's Scientific Sessions. Ford declined to provide a timeline or pricing details for the planned device. BTIG analyst Marie Thibault wrote in June that Abbott's management expects a launch sometime next year. The company is also partnering with insulin pump companies, including Tandem, Sequel Med Tech and Beta Bionics, to support the new sensor. 'I think this is going to be a real next-level, significant change in the CGM market,' Ford said, specifically for intensive insulin users. Abbott's electrophysiology business, with the company's new Volt pulsed field ablation device to treat cardiac arrhythmias, grew by 11.5% to $700 million. Recommended Reading 'We are not rolling over': J&J electrophysiology unit rebounds amid PFA rivalry Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store